CT/MRI

DIAGNOSTIC_TEST3 trials

Sponsors

Memorial Sloan Kettering Cancer Center, National Cancer Institute (NCI), Ricoh USA, Inc.

Conditions

Adenosquamous Carcinoma of the PancreasChondrosarcomaEsophageal CancerFibrosarcomaFibrous HistiocytomaGastroesophageal Junction CancerOsteosarcomaSarcoma, Ewing

Phase 2

Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer

CompletedNCT00917462

Memorial Sloan Kettering Cancer CenterEsophageal Cancer, Gastroesophageal Junction Cancer

Start: 2009-06-30End: 2018-08-31Updated: 2019-03-27

Superenhancer Inhibitor Minnelide in Advanced Refractory Adenosquamous Carcinoma of the Pancreas (ASCP)

CompletedNCT04896073

National Cancer Institute (NCI)Adenosquamous Carcinoma of the Pancreas

Start: 2022-03-07End: 2025-03-30Updated: 2026-08-14

Unknown Phase

A Study to Evaluate the Utilization of 3D Printed Models in Pre-Operative Planning

RecruitingNCT06387485

Ricoh USA, Inc.Chondrosarcoma, Fibrosarcoma, Fibrous Histiocytoma +2

Start: 2024-03-01End: 2027-07-31Target: 150Updated: 2026-02-06

Related Papers

Abstract PO-054: A phase II trial of the super-enhancer inhibitor Minnelide in advanced refractory adenosquamous carcinoma of the pancreas (ASCP)

Cancer Research2021-11-151 citations

Phase II Trial of Sorafenib in Patients with Chemotherapy Refractory Metastatic Esophageal and Gastroesophageal (GE) Junction Cancer

PLoS ONE2015-08-1449 citations